Cns Pharmaceuticals Inc (CNSP)

Apr 1, 2025, 8:05 AM EDT - 25 days ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Mar 25, 2025, 12:05 PM EDT - 4 weeks ago

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Mar 25, 2025, 8:00 AM EDT - 4 weeks ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Feb 26, 2025, 9:05 AM EST - 2 months ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 20, 2025, 9:00 AM EST - 2 months ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 19, 2025, 9:00 AM EST - 2 months ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:30 AM EST - 2 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

Feb 18, 2025, 9:00 AM EST - 2 months ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 10, 2025, 8:00 AM EST - 2 months ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Dec 5, 2024, 9:10 AM EST - 5 months ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Nov 25, 2024, 9:00 AM EST - 5 months ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 18, 2024, 8:55 AM EST - 5 months ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 15, 2024, 9:10 AM EST - 5 months ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 9:15 AM EST - 6 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 1, 2024, 9:00 AM EDT - 6 months ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Oct 23, 2024, 2:50 PM EDT - 6 months ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 10, 2024, 9:00 AM EDT - 7 months ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 8, 2024, 9:15 AM EDT - 7 months ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Sep 23, 2024, 9:00 AM EDT - 7 months ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 12, 2024, 9:00 AM EDT - 8 months ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 4, 2024, 9:05 AM EDT - 8 months ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 8 months ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Aug 27, 2024, 9:10 AM EDT - 8 months ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 22, 2024, 9:15 AM EDT - 8 months ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 15, 2024, 8:00 AM EDT - 9 months ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:00 AM EDT - 9 months ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 25, 2024, 9:05 AM EDT - 9 months ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 16, 2024, 9:15 AM EDT - 10 months ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 3, 2024, 11:10 AM EDT - 10 months ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

May 20, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 16, 2024, 7:45 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Apr 22, 2024, 10:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Apr 1, 2024, 5:00 PM EDT - 1 year ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Apr 1, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

GILD REVB ZLAB

Jan 29, 2024, 9:00 PM EST - 1 year ago

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Jan 18, 2024, 8:45 AM EST - 1 year ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Jan 17, 2024, 8:45 AM EST - 1 year ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Dec 18, 2023, 8:35 AM EST - 1 year ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Dec 6, 2023, 9:00 AM EST - 1 year ago

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Nov 22, 2023, 9:05 AM EST - 1 year ago

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Nov 16, 2023, 10:00 AM EST - 1 year ago

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

Nov 15, 2023, 8:00 AM EST - 1 year ago

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

Oct 19, 2023, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

Oct 16, 2023, 9:00 AM EDT - 1 year ago

Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals' Innovative Approach To Treatment Could Offer Hope

Oct 11, 2023, 8:45 AM EDT - 1 year ago

CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date

Sep 7, 2023, 8:45 AM EDT - 1 year ago

CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)

Sep 5, 2023, 8:45 AM EDT - 1 year ago

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:35 AM EDT - 1 year ago

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy